secwatch.observer — SEC 8-K summary
======================================

Issuer:     Sagimet Biosciences Inc. (SGMT)
CIK:        0001400118
Form:       8-K
Filed at:   2023-11-13T23:59:59+00:00
Accession:  0001104659-23-116795
Event type: earnings
Sentiment:  neutral
Materiality: 0.45
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Sagimet reports Q3 net loss of $6.4M; cash $101.8M; NASH data due Q1 2024
-------------------------------------------------------------------------

- Net loss $6.4M vs $7.5M in Q3 2022; revenue $2.0M from milestone vs zero year-ago.
- Cash $101.8M, expected to fund operations at least 12 months.
- Phase 2b FASCINATE-2 (denifanstat) week 52 liver biopsy results expected Q1 2024.
- Two AASLD abstracts accepted; preclinical FASN inhibitor + semaglutide combo data shown.
- Ascletis enrolled 120 patients in Phase 3 denifanstat + bevacizumab for recurrent GBM.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1400118/000110465923116795/0001104659-23-116795-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1400118/000110465923116795/tm2330502d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-116795

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer